Search Within

Pamela R Drullinsky

Formats
  1. Meeting Abstract (58)
  2. Journal Article (31)
  3. Research Letter (1)
  4. Review (1)
Groups
  1. Breast Medicine Service (91)
  2. Department of Medicine (91)
  3. Solid Tumor Oncology Division (91)
  4. Survivorship Research (69)
  5. Epidemiology and Biostatistics (47)
  6. Population Sciences Research Program (46)

More Groups

People
  1. Andrew Zelenetz (35)
  2. Matthew Matasar (32)
  3. Anita Kumar (31)
  4. David Straus (31)
  5. Paul Hamlin (31)
  6. Alison Moskowitz (26)

More People

Years
  1. 2024 (4)
  2. 2023 (1)
  3. 2022 (9)
  4. 2021 (10)
  5. 2020 (8)
  6. 2019 (4)

More Years

Publications
  1. Journal of Clinical Oncology (20)
  2. Blood (17)
  3. Breast Cancer Research and Treatment (10)
  4. Cancer Research (9)
  5. Hematological Oncology (6)
  6. Clinical Cancer Research (4)

More Publications

Publishers
  1. American Society of Clinical Oncology (20)
  2. American Society of Hematology (17)
  3. American Association for Cancer Research (13)
  4. Springer (10)
  5. Elsevier Inc. (8)
  6. Wiley Blackwell (6)

More Publishers

Results (91)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Phase I study of bendamustine, rituximab, ibrutinib, and venetoclax in relapsed, refractory mantle cell lymphoma
    Meeting Abstract

    Kumar, A.; Batlevi, C.; Drullinsky, P.; Grieve, C.; Laraque, L.; Joseph, A.; Mahajan, N.; Matasar, M.; Straus, D.; Zelenetz, A.; more...
    Hematological Oncology (2021)

    Fulltext@MSK | Save
  • RETRACTED: Alpelisib plus fulvestrant in PIK3CA-mutated, hormone receptor-positive advanced breast cancer after a CDK4/6 inhibitor (BYLieve): One cohort of a phase 2, multicentre, open-label, non-comparative study
    Journal Article

    Rugo, H. S.; Lerebours, F.; Ciruelos, E.; Drullinsky, P.; Ruiz-Borrego, M.; Neven, P.; Park, Y. H.; Prat, A.; Bachelot, T.; Juric, D.; more...
    Lancet Oncology (2021)

    Fulltext@MSK | Save
  • Alpelisib + letrozole in patients with PIK3CA-mutated, hormone-receptor positive (HR+), human epidermal growth factor receptor-2-negative (HER2-) advanced breast cancer (ABC) previously treated with a cyclin-dependent kinase 4/6 inhibitor (CDK4/6i) + fulvestrant: BYLieve study results
    Meeting Abstract

    Rugo, H. S.; Lerebours, F.; Juric, D.; Turner, N.; Chia, S.; Drullinsky, P.; Prat, A.; Vázquez, R. V.; Akdere, M.; Arce, C.; more...
    Cancer Research (2021)

    Fulltext@MSK | Save
  • Phase III randomized study of taselisib or placebo with fulvestrant in estrogen receptor-positive, PIK3CA-mutant, HER2-negative, advanced breast cancer: The SANDPIPER trial
    Journal Article

    Dent, S.; Cortés, J.; Im, Y. H.; Diéras, V.; Harbeck, N.; Krop, I. E.; Wilson, T. R.; Cui, N.; Schimmoller, F.; Hsu, J. Y.; more...
    Annals of Oncology (2021)

    Fulltext@MSK | Save
  • Interim analysis from a prospective multicenter study of next-generation sequencing minimal residual disease assessment and CT monitoring for surveillance after frontline treatment in diffuse large B-cell lymphoma
    Meeting Abstract

    Kumar, A.; Westin, J.; Schuster, S. J.; Nowakowski, G. S.; Lossos, I. S.; Batlevi, C. L.; Caron, P.; Drullinsky, P.; Gerecitano, J.; Hamilton, A.; more...
    Blood (2020)

    Fulltext@MSK | Save
  • Frontline sequential immunochemotherapy plus lenalidomide for mantle cell lymphoma incorporating MRD evaluation: Phase II, investigator-initiated, single-center study
    Meeting Abstract

    Epstein-Peterson, Z. D.; Batlevi, C. L.; Caron, P.; Dogan, A.; Drullinsky, P.; Gerecitano, J.; Hamilton, A.; Hamlin, P. A.; Ho, C.; Jacob, A. P.; more...
    Blood (2020)

    Fulltext@MSK | Save
  • Alpelisib (ALP) + fulvestrant (FUL) in patients (pts) with PIK3CA-mutated (mut) hormone receptor-positive (HR plus ), human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (ABC) previously treated with cyclin-dependent kinase 4/6 inhibitor (CDKi) plus aromatase inhibitor (AI): BYLieve study results
    Meeting Abstract

    Rugo, H. S.; Lerebours, F.; Ciruelos, E.; Drullinsky, P.; Borrego, M. R.; Neven, P.; Park, Y. H.; Prat, A.; Bachelot, T.; Juric, D.; more...
    Journal of Clinical Oncology (2020)

    Fulltext@MSK | Save
  • Prevalence and characterization of dermatologic adverse events related to alpelisib (BYL719) in breast cancer patients
    Meeting Abstract

    Barrios, D. M.; Wang, D. G.; Blinder, V. S.; Bromberg, J.; Drullinsky, P.; Funt, S. A.; Jhaveri, K. L.; Lake, D.; Lyons, T.; Modi, S.; more...
    Journal of Clinical Oncology (2020)

    Fulltext@MSK | Save
  • Treatment considerations for patients with advanced breast cancer who receive alpelisib after CDK4/6 inhibitor-based therapy
    Meeting Abstract

    Alano, T.; Rowan, J.; Drullinsky, P.
    Oncology Nursing Forum (2020)

    Fulltext@MSK | Save
  • Dermatologic adverse events related to the PI3Kα inhibitor alpelisib (BYL719) in patients with breast cancer
    Journal Article

    Wang, D. G.; Barrios, D. M.; Blinder, V. S.; Bromberg, J. F.; Drullinsky, P. R.; Funt, S. A.; Jhaveri, K. L.; Lake, D. E.; Lyons, T.; Modi, S.; more...
    Breast Cancer Research and Treatment (2020)

    Fulltext@MSK | Save